Novo Nordisk A/S: Ryzodeg(R) (insulin degludec/insulin aspart)

Novo Nordisk A/S: Ryzodeg(R) (insulin degludec/insulin aspart) passed the review by the First Committee on Drugs of Pharmaceutical Affairs in Japan

BAGSVAERD, DENMARK -- (Marketwire) -- 12/03/12 -- Novo Nordisk today announced that Ryzodeg(R) (insulin degludec/insulin aspart) has passed the review by the First Committee on Drugs of Japan's Pharmaceutical Affairs. The remaining step in the regulatory process is an approval from the Ministry of Health, Labour and Welfare.

Company announcement No 78 / 2012: http://hugin.info/2013/R/1661613/538373.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1661613]

Further information Media: Mike Rulis +45 4442 3573 mike@novonordisk.com

Ambre Morley (US) +1 609 216 5240 abmo@novonordisk.com

Investors: Kasper Roseeuw Poulsen +45 4442 4303 krop@novonordisk.com

Frank Daniel Mersebach +45 4442 0604 fdni@novonordisk.com

Lars Borup Jacobsen +45 3075 3479 lbpj@novonordisk.com

Jannick Lindegaard (US) +1 609 786 4575 jlis@novonordisk.com